LANCET, cilt.379, sa.9825, ss.1498-1507, 2012 (SCI-Expanded)
Background Basal insulin therapy does not stop loss of beta-cell function, which is the hallmark of type 2 diabetes mellitus, and thus diabetes control inevitably deteriorates. Insulin degludec is a new, ultra-longacting basal insulin. We aimed to assess efficacy and safety of insulin degludec compared with insulin glargine in patients with type 2 diabetes mellitus.